UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

Breast cancer research and treatment, 2018-07, Vol.170 (2), p.213-219

2018

Volltextzugriff (PDF)

Mutant p53 as a target for cancer treatment

European journal of cancer (1990), 2017-09, Vol.83, p.258-265

2017

Volltextzugriff (PDF)

Targeting p53 for the treatment of cancer

Seminars in cancer biology, 2022-02, Vol.79, p.58-67

2022

Volltextzugriff (PDF)

Vitamin D receptor as a target for breast cancer therapy

Endocrine-related cancer, 2017-04, Vol.24 (4), p.181-195

2017

Volltextzugriff (PDF)

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer

Translational oncology, 2024-08, Vol.46, p.102025, Article 102025

2024

Volltextzugriff (PDF)

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells

Endocrine-related cancer, 2016-04, Vol.23 (4), p.323-334

2016

Volltextzugriff (PDF)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

Translational oncology, 2018-12, Vol.11 (6), p.1343-1349

2018

Volltextzugriff (PDF)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Cancers, 2019-02, Vol.11 (2), p.197

2019

Volltextzugriff (PDF)

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Breast cancer research and treatment, 2020, Vol.179 (1), p.47-56

2020

Volltextzugriff (PDF)

Vitamin D analogues: Potential use in cancer treatment

Critical reviews in oncology/hematology, 2017-04, Vol.112, p.190-197

2017

Volltextzugriff (PDF)

Characterizing the tumor microenvironment in rare renal cancer histological types

The journal of pathology. Clinical research, 2022-01, Vol.8 (1), p.88-98

2022

Volltextzugriff (PDF)

p53 as a target for the treatment of cancer

Cancer treatment reviews, 2014-12, Vol.40 (10), p.1153-1160

2014

Volltextzugriff (PDF)

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

Cancer letters, 2018-02, Vol.414, p.99-106

2018

Volltextzugriff (PDF)

Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers

American journal of epidemiology, 2021-06, Vol.190 (6), p.962-976

2021

Volltextzugriff (PDF)

Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13121-e13121

2018

Volltextzugriff (PDF)

MYC as a therapeutic target for the treatment of triple-negative breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12550-e12550

2019

Volltextzugriff (PDF)

Abstract PO-192: Comparing the association of self-reported race-ethnicity and genetic ancestry with all-cause mortality: A pan-cancer survivor analysis in the PLCO Screening Trial

Cancer epidemiology, biomarkers & prevention, 2022-01, Vol.31 (1_Supplement), p.PO-192-PO-192

2022

Volltextzugriff (PDF)

Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14098-e14098

2017

Volltextzugriff (PDF)

Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers: The Sherlock-Lung Study

American journal of epidemiology, 2021-06, Vol.190 (6), p.962-976

2021

Volltextzugriff (PDF)

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1082-1082

2016

Volltextzugriff (PDF)

The vitamin D receptor as a target for the treatment of breast cancer: Studies with the low calcemic vitamin D analog, inecalcitol

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12011-e12011

2016

Volltextzugriff (PDF)

The vitamin D receptor: A therapeutic target for the treatment of breast cancer?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.534-534

2015

Volltextzugriff (PDF)

p53 in cancer: ready for therapeutic targeting?

Translational cancer research, 2016-12, Vol.5 (6), p.627-631

2016

Volltextzugriff (PDF)

Enzalutamide: A new hormonal treatment for triple-negative breast cancer?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1071-1071

2015

Volltextzugriff (PDF)

PRIMA-1 MET (APR-246): A novel targeted therapy for triple negative breast cancer?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e12072-e12072

2015

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Oncology
(13)
Humans
(10)
Breast Cancer
(7)
Apr-246
(6)
Mutation
(6)
Tumors
(6)
Female
(5)
P53
(5)
Tumor Suppressor Protein P53 - Genetics
(5)
Antineoplastic Agents - Pharmacology
(4)
Apoptosis
(4)
Cancer
(4)
Cell Line, Tumor
(4)
Neoplasms - Drug Therapy
(4)
P53 Protein
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer Therapies
(3)
Cell Proliferation - Drug Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

Mutant p53 as a target for cancer treatment

Targeting p53 for the treatment of cancer

Vitamin D receptor as a target for breast cancer therapy

Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Vitamin D analogues: Potential use in cancer treatment

Characterizing the tumor microenvironment in rare renal cancer histological types

p53 as a target for the treatment of cancer

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers

Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?

MYC as a therapeutic target for the treatment of triple-negative breast cancer

Abstract PO-192: Comparing the association of self-reported race-ethnicity and genetic ancestry with all-cause mortality: A pan-cancer survivor analysis in the PLCO Screening Trial

Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells

Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers: The Sherlock-Lung Study

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246

The vitamin D receptor as a target for the treatment of breast cancer: Studies with the low calcemic vitamin D analog, inecalcitol

The vitamin D receptor: A therapeutic target for the treatment of breast cancer?

p53 in cancer: ready for therapeutic targeting?

Enzalutamide: A new hormonal treatment for triple-negative breast cancer?

PRIMA-1 MET (APR-246): A novel targeted therapy for triple negative breast cancer?

Suchergebnisse filtern